# SAFFRON-301 (NCT04921358)

> Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: sitravatinib plus tislelizumab
- Indication: locally advanced or metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04921358
- Phase: PHASE3
- Status: TERMINATED
- Sponsor: BeiGene
- Conditions: Non-Small Cell Lung Cancer (NSCLC)
- Interventions: Tislelizumab; Docetaxel; Sitravatinib
- Enrollment: 377
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

## Indexed commentary on SAFFRON-301 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=saffron-301-nct04921358